Bleeding in renal failure: a possible role of vascular prostacyclin (PGI2). 1979

G Remuzzi, and D Marchesi, and A E Cavenaghi, and M Livio, and M B Donati, and G de Gaetano, and G Mecca

Specimens of venous tissues from a group of 25 patients with chronic uremia and 7 patients with acute renal failure generated significantly higher PGI2-like (platelet aggregation inhibiting) activity than venous tissues from 30 normal subjects. After repeated washings, when this activity could barely be detected in the controls, pronounced inhibitory activity was still evident in samples containing venous tissues from uremic patients. Both prolonged bleeding times and increased PGI2-like activity returned to normal in 4 acute uremic patients on restoration of their renal function. These findings may be relevant to the pathogenesis of bleeding in renal failure.

UI MeSH Term Description Entries
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011449 Prostaglandin Endoperoxides Precursors in the biosynthesis of prostaglandins and thromboxanes from arachidonic acid. They are physiologically active compounds, having effect on vascular and airway smooth muscles, platelet aggregation, etc. Endoperoxides, Prostaglandin
D011453 Prostaglandins A group of compounds derived from unsaturated 20-carbon fatty acids, primarily arachidonic acid, via the cyclooxygenase pathway. They are extremely potent mediators of a diverse group of physiological processes. Prostaglandin,Prostanoid,Prostanoids
D011464 Epoprostenol A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from PROSTAGLANDIN ENDOPEROXIDES in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension (HYPERTENSION, PULMONARY). Prostacyclin,Prostaglandin I2,Epoprostanol,Epoprostenol Sodium,Epoprostenol Sodium Salt, (5Z,9alpha,11alpha,13E,15S)-Isomer,Flolan,Prostaglandin I(2),Veletri
D001760 Bleeding Time Duration of blood flow after skin puncture. This test is used as a measure of capillary and platelet function. Aspirin Tolerance Test,Bleeding Time, Template,Duke Method,Ivy Method,Template Bleeding Time,Aspirin Tolerance Tests,Bleeding Times,Bleeding Times, Template,Method, Duke,Method, Ivy,Template Bleeding Times,Test, Aspirin Tolerance,Tests, Aspirin Tolerance,Time, Bleeding,Time, Template Bleeding,Times, Bleeding,Times, Template Bleeding,Tolerance Test, Aspirin,Tolerance Tests, Aspirin
D001792 Blood Platelets Non-nucleated disk-shaped cells formed in the megakaryocyte and found in the blood of all mammals. They are mainly involved in blood coagulation. Platelets,Thrombocytes,Blood Platelet,Platelet,Platelet, Blood,Platelets, Blood,Thrombocyte
D005260 Female Females
D006470 Hemorrhage Bleeding or escape of blood from a vessel. Bleeding,Hemorrhages

Related Publications

G Remuzzi, and D Marchesi, and A E Cavenaghi, and M Livio, and M B Donati, and G de Gaetano, and G Mecca
March 1981, Lancet (London, England),
G Remuzzi, and D Marchesi, and A E Cavenaghi, and M Livio, and M B Donati, and G de Gaetano, and G Mecca
January 1978, Acta biologica et medica Germanica,
G Remuzzi, and D Marchesi, and A E Cavenaghi, and M Livio, and M B Donati, and G de Gaetano, and G Mecca
December 1977, Thrombosis research,
G Remuzzi, and D Marchesi, and A E Cavenaghi, and M Livio, and M B Donati, and G de Gaetano, and G Mecca
August 1985, European journal of pharmacology,
G Remuzzi, and D Marchesi, and A E Cavenaghi, and M Livio, and M B Donati, and G de Gaetano, and G Mecca
December 1977, Lancet (London, England),
G Remuzzi, and D Marchesi, and A E Cavenaghi, and M Livio, and M B Donati, and G de Gaetano, and G Mecca
September 1976, British medical journal,
G Remuzzi, and D Marchesi, and A E Cavenaghi, and M Livio, and M B Donati, and G de Gaetano, and G Mecca
June 1977, British medical journal,
G Remuzzi, and D Marchesi, and A E Cavenaghi, and M Livio, and M B Donati, and G de Gaetano, and G Mecca
April 1992, Angiology,
G Remuzzi, and D Marchesi, and A E Cavenaghi, and M Livio, and M B Donati, and G de Gaetano, and G Mecca
January 1983, Hypertension (Dallas, Tex. : 1979),
G Remuzzi, and D Marchesi, and A E Cavenaghi, and M Livio, and M B Donati, and G de Gaetano, and G Mecca
January 1983, Intensive care medicine,
Copied contents to your clipboard!